Compared to individuals with IDH-wild-type tumors, people with IDH-mutant gliomas have various treatment choices, like chemotherapy and radiation, and tend to respond better to particular medicines. The prognostic significance of IDH mutations in juvenile patients is less evident. This evidence concerns the gene IDH1 and central nervous system cancer.